Teva Pharma, Israeli institutes sign agreement to boost drug research on cancer treatments

A partnership with Tel Aviv University will focus on research and development in cancer and brain studies, while a collaboration with the Weizmann Institute of Science will try to identify antibodies for cancer treatment, Israel-based Teva said.

New Delhi: Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments.

The world's largest generic drugmaker has been looking to expand its speciality portfolio and said it is seeking more than 400 new laboratories within Israeli academia.

A partnership with Tel Aviv University will focus on research and development in cancer and brain studies, while a collaboration with the Weizmann Institute of Science will try to identify antibodies for cancer treatment, Israel-based Teva said.

Read Also: Teva Pharma, 3 others reach tentative deal to settle an opioid lawsuit

"Teva is planning to carry out much more cutting-edge collaboration with researchers from leading universities and medical centres in Israel in the fields of oncology, immunology and brain studies - areas in which Israel has unique research capabilities," said Steffen Nock, head of Teva's innovative research team.

Read Also: Teva’s UK arm recalls some batches of Ranitidine: Medicines watchdog